Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma
Human Cell · 2025
DOI: 10.1007/s13577-025-01253-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2025. Verfasst von Chenyang Xu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Primary ovarian squamous cell carcinoma (POSCC) represents an exceedingly rare subtype of epithelial ovarian cancer (EOC) characterized by a cryptic etiology and insidious onset. The rarity and high mortality associated with pure primary ovarian squamous cell carcinoma (SCC) make it challenging to conduct large randomized controlled studies. Furthermore, there are currently no commercially available ovarian SCC cell lines for research purposes, necessitating the urgent establishment of novel lines. To our knowledge, this study reports the first preclinical model of primary ovarian squamous cell carcinoma (POSCC), denoted as ZOC254. We have detailed the establishment and characterization of ZOC254, derived from a 64-year-old female patient, which preserves the primary tumor's original traits across various levels during prolonged in vitro expansion. Whole-exome sequencing (WES) of both the primary tumor and derived cell line revealed homologous recombination deficiency (HRD) and high tumor mutational burden (TMB). ZOC254 also exhibited the PIK3CA: p.E542K mutation associated with targeted therapy. The effectiveness of olaparib, everolimus, and conventional chemotherapeutic agents for ovarian cancer was preliminarily assessed on the growth of patient-derived cells (PDC). The POSCC cell line and derived xenograft transplantation model reported in this study serve the purpose of broadening the resources accessible for preclinical investigations into ovarian squamous carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China.
- Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
- Department of Pathology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, Zhejiang Province, China.
- Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China. yingls@zjcc.org.cn.
- Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. yingls@zjcc.org.cn.
- Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China. sudan@zjcc.org.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, C., Xu, W., Wu, C., Xu, C., Ma, Z., Wang, J., Zhuo, Y., Cai, X., Zhang, Y., Lyu, Y., Wang, J., Huang, M., Sun, S., Feng, T., Ying, L., & Su, D. (2025). Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma. Human Cell. https://doi.org/10.1007/s13577-025-01253-4
Vancouver
Xu C, Xu W, Wu C, Xu C, Ma Z, Wang J, et al. Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma. Human Cell. 2025. doi:10.1007/s13577-025-01253-4
BibTeX
@article{Xu2025,
author = {Xu, Chenyang and Xu, Weiming and Wu, Conghui and Xu, Chen and Ma, Zhengxiao and Wang, Jiamin and Zhuo, Yue and Cai, Xinan and Zhang, Yuting and Lyu, Yingqi and Wang, Jinchao and Huang, Minran and Sun, Shu and Feng, Tingting and Ying, Lisha and Su, Dan},
title = {Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma},
journal = {Human Cell},
year = {2025},
doi = {10.1007/s13577-025-01253-4}
}
EUVIMED